Literature DB >> 2284992

Nuclear magnetic resonance and lipids of the plasma from patients with intracranial tumours.

S Pomeranz1, E Segal, E Ashkenazi, Y Hite, S Constantini.   

Abstract

The plasma of fifteen patients with malignant primary intracranial central nervous system (CNS) neoplasms was examined using proton nuclear magnetic resonance (NMR) and lipid level analysis. Twenty-three benign intracranial neoplasms and twelve non-CNS, non-malignancy patients served as control. At 300 MHz the NMR mean line width of plasma with malignant tumours was (+/- 2 SE) 37.2 +/- 3.0 Hz and for benign tumours 33.5 +/- 3.0 Hz (P = 0.09). The mean plasma triglyceride level for the malignancy patients was 100 +/- 25 mg/decilitre and 173 +/- 74 mg/decilitre for the patients with benign tumours (P = 0.07). The mean plasma cholesterol was 182 +/- 42 mg/decilitre for the malignancy patients and for the patients with benign tumours 241 +/- 29 mg/decilitre (P = 0.03). Unfortunately overlaps of the values of the different groups, in spite of statistically significant differences, detracts from the clinical usefulness of these criteria. Attempts to combine these values and correct for tumour volume, as calculated from computerized tomography, did not improve the differentiation between these two groups. Although it has been reported that plasma NMR and lipid levels can differentiate between malignant and benign tumours in general and in the central nervous system, these criteria are not adequately sensitive and specific to replace histology for the definite diagnosis of central nervous system tumours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2284992     DOI: 10.1007/bf01809460

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  10 in total

1.  Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma.

Authors:  M P Mims; J D Morrisett; C A Mattioli; A M Gotto
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

2.  Reactive gliosis simulating butterfly glioma: a neuroradiological case study.

Authors:  C Cazenave; S Reid; C Virapongse; S Hunter
Journal:  Neurosurgery       Date:  1986-11       Impact factor: 4.654

3.  Oncolipids? A possible new approach to diagnosis of cancer.

Authors:  P S Schein
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

4.  Effect of triglyceride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

5.  Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.

Authors:  P Wilding; M B Senior; T Inubushi; M L Ludwick
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

6.  Serum lipoprotein levels in patients with cancer.

Authors:  U E Nydegger; R E Butler
Journal:  Cancer Res       Date:  1972-08       Impact factor: 12.701

7.  Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.

Authors:  E T Fossel; J M Carr; J McDonagh
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

8.  Hyperlipidemia as a biochemical basis of magnetic resonance plasma test for cancer.

Authors:  K T Holmes; W B Mackinnon; G L May; L C Wright; M Dyne; M H Tattersall; C E Mountford; D Sullivan
Journal:  NMR Biomed       Date:  1988-02       Impact factor: 4.044

9.  Incidental lesions noted on magnetic resonance imaging of the brain: prevalence and clinical significance in various age groups.

Authors:  I A Awad; R F Spetzler; J A Hodak; C A Awad; F Williams; R Carey
Journal:  Neurosurgery       Date:  1987-02       Impact factor: 4.654

10.  1H and 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms.

Authors:  J Peeling; G Sutherland; K Marat; E Tomchuk; E Bock
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.